ArticleFrontiers in immunology2025
Case Report: Bilateral adrenal hemorrhage in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Adrenal involvement in antiphospholipid syndrome and SLE-spectrum disease: a systematic review and pooled individual-patient analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a rare and life-threatening complication of bilateral adrenal hemorrhage (AH) in a 15-year-old female with overlapping systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The patient presented with prolonged abdominal pain, low-grade fever, and lower limb pain. Imaging revealed bilateral adrenal hemorrhages, while laboratory investigations confirmed triple-positive antiphospholipid antibodies (ACA-IgG, ACA-IgM, anti-β2 glycoprotein I) and SLE-related serological markers. Management involved dual-pathway therapy: immunosuppression (prednisone, hydroxychloroquine) for SLE and anticoagulation (low-molecular-weight heparin, warfarin) for APS. Despite initial improvement, adrenal insufficiency developed, requiring glucocorticoid replacement. Follow-up demonstrated stabilized clinical status and reduced adrenal lesions. This case underscores the diagnostic challenges of AH in SLE-APS overlap and emphasizes the necessity of combining immunosuppressive and anticoagulant therapies to address both autoimmune inflammation and thrombotic risks. Early recognition and multidisciplinary management are critical to prevent adrenal crisis and improve outcomes in such complex autoimmune-thrombotic pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.